

# Jia Luo

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8907588/publications.pdf>

Version: 2024-02-01

13  
papers

847  
citations

1163117

8  
h-index

1281871

11  
g-index

13  
all docs

13  
docs citations

13  
times ranked

1817  
citing authors

#	ARTICLE	IF	CITATIONS
1	Deep Learning to Estimate RECIST in Patients with NSCLC Treated with PD-1 Blockade. <i>Cancer Discovery</i> , 2021, 11, 59-67.	9.4	38
2	Erlotinib and Trametinib in Patients With EGFR-Mutant Lung Adenocarcinoma and Acquired Resistance to a Prior Tyrosine Kinase Inhibitor. <i>JCO Precision Oncology</i> , 2021, 5, 55-64.	3.0	10
3	Success and failure of additional immune modulators in steroid-refractory/resistant pneumonitis related to immune checkpoint blockade. , 2021, 9, e001884.		27
4	Immunotherapy-Mediated Thyroid Dysfunction: Genetic Risk and Impact on Outcomes with PD-1 Blockade in Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 5131-5140.	7.0	40
5	Association of prior radiation dose to the cardiopulmonary system with COVID-19 outcomes in patients with cancer. <i>Radiotherapy and Oncology</i> , 2021, 161, 115-117.	0.6	2
6	Beyond Steroids: Immunosuppressants in Steroid-Refractory or Resistant Immune-Related Adverse Events. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1759-1764.	1.1	49
7	Outcomes to first-line pembrolizumab in patients with PD-L1-high (>50%) non-small cell lung cancer and a poor performance status. , 2020, 8, e001007.		36
8	Prognostic and Predictive Impact of Circulating Tumor DNA in Patients with Advanced Cancers Treated with Immune Checkpoint Blockade. <i>Cancer Discovery</i> , 2020, 10, 1842-1853.	9.4	179
9	CNS Metastases in Patients With MET Exon 14-Altered Lung Cancers and Outcomes With Crizotinib. <i>JCO Precision Oncology</i> , 2020, 4, 871-876.	3.0	14
10	Impact of PD-1 Blockade on Severity of COVID-19 in Patients with Lung Cancers. <i>Cancer Discovery</i> , 2020, 10, 1121-1128.	9.4	206
11	MET-dependent solid tumours – molecular diagnosis and targeted therapy. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 569-587.	27.6	165
12	Making Checkpoint Inhibitors Part of Treatment of Patients With Locally Advanced Lung Cancers: The Time Is Now. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2020, 40, e159-e170.	3.8	7
13	Circulating Tumor DNA Analysis to Assess Risk of Progression after Long-term Response to PD-(L)1 Blockade in NSCLC. <i>Clinical Cancer Research</i> , 2020, 26, 2849-2858.	7.0	74